文献速递乳腺MR

不同乳腺癌风险指征女性的筛查乳腺MRI表现

Performance of Screening Breast MRI across Women with Different Elevated Breast Cancer Risk Indications.
PubMed 文献 · Radiology · 2019-05-07

该回顾性研究分析了2011至2014年间2637名女性共5170次筛查乳腺MRI,按BRCA突变/胸部放疗史、家族史、个人乳腺癌史及高危病变史分组比较筛查效能。BRCA/RT组癌症检出率最高(26/1000),家族史组最低(8/1000)且阳性预测值较低;个人乳腺癌史和高危病变组的检出率与BRCA/RT组无显著差异。作者认为个人乳腺癌史或高危病变女性应考虑筛查乳腺MRI。

要点

  • BRCA突变或胸部放疗史女性筛查乳腺MRI的癌症检出率最高,为26/1000次检查。
  • 家族史组癌症检出率最低(8/1000)且活检阳性预测值较低(14%)。
  • 个人乳腺癌史和高危病变组癌症检出率与BRCA/RT组无显著差异。

核心结论

  • 筛查乳腺MRI应考虑用于有个人乳腺癌史或高危病变的女性;家族史女性筛查MRI表现较差,提示更好的风险评估策略可能使这些女性获益。

研究设计与样本

  • 回顾性病历审查,纳入2011至2014年间2637名女性的5170次筛查乳腺MRI检查,按BRCA突变/胸部放疗史、家族史、个人乳腺癌史、高危病变史分组比较筛查效能。

诊断标准与关键数值

  • 癌症检出率:BRCA/RT组26/1000次检查(95%CI 16,43),个人乳腺癌史组12/1000(95%CI 9,17),高危病变组15/1000(95%CI 7,32),家族史组8/1000(95%CI 4,14);活检阳性预测值:BRCA/RT组41%(95%CI 26%,56%),个人乳腺癌史组41%(95%CI 31%,52%),高危病变组36%(95%CI 17%,60%),家族史组14%(95%CI 8%,25%)。

临床应用与阅片要点

  • 作者认为,有个人乳腺癌史或高危病变的女性应考虑筛查乳腺MRI;家族史女性筛查MRI表现较差,提示更好的风险评估策略可能使这些女性获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Screening breast MRI is recommended for women with BRCA mutation or a history of chest radiation, but guidelines are equivocal for MRI screening of women with a personal history of breast cancer or high-risk lesion. Purpose To evaluate screening breast MRI performance across women with different elevated breast cancer risk indications. Materials and Methods All screening breast MRI examinations performed between 2011 and 2014 underwent retrospective medical record review. Indications for screening were as follows: BRCA mutation carrier or history of chest radiation (BRCA/RT group), family history of breast cancer (FH group), personal history of breast cancer (PH group), and history of high-risk lesion (HRL group). Screening performance metrics were calculated and compared among indications by using logistic regression adjusted for age, available prior MRI, mammographic density, examination year, and multiple risk factors. Results There were 5170 screening examinations in 2637 women (mean age, 52 years; range, 23-86 years); 67 breast cancers were detected. The cancer detection rate (CDR) was highest in the BRCA/RT group (26 per 1000 examinations; 95% confidence interval [CI]: 16, 43 per 1000 examinations), intermediate for those in the PH and HRL groups (12 per 1000 examinations [95% CI: 9, 17 per 1000 examinations] and 15 per 1000 examinations [95% CI: 7, 32 per 1000 examinations], respectively), and lowest for those in the FH group (8 per 1000 examinations; 95% CI: 4, 14 per 1000 examinations). No difference in CDR was evident for the PH or HRL group compared with the BRCA/RT group (P = .14 and .18, respectively). The CDR was lower for the FH group compared with the BRCA/RT group (P = .02). No difference was evident in positive predictive value for biopsies performed (PPV3) for the BRCA/RT group (41%; 95% CI: 26%, 56%) compared with the PH (41%; 95% CI: 31%, 52%; P = .63) or HRL (36%, 95% CI: 17%, 60%; P = .37) groups. PPV3 was lower for the FH group (14%; 95% CI: 8%, 25%; P = .048). Conclusion Screening breast MRI should be considered for women with a personal history of breast cancer or high-risk lesion. Worse screening MRI performance in patients with a family history of breast cancer suggests that better risk assessment strategies may benefit these women. © RSNA, 2019.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Sippo DA, Burk KS, Mercaldo SF, et al. Performance of Screening Breast MRI across Women with Different Elevated Breast Cancer Risk Indications. Radiology. 2019. PMID: 31063080. doi:10.1148/radiol.2019181136

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。